NCT02581657View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM

PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

PE0139 Injection

PE0139 Injection

DRUG

Placebo Injection

Placebo Injection

Trial Locations (6)

33012

Indago Research and Health Center, Inc., Hialeah

34208

Meridien Research, Bradenton

36207

Pinnacle Research Group, LLC, Anniston

70119

New Orleans Center for Clinical Research, New Orleans

90255

National Research Institute, Huntington Park

98057

Rainier Clinical Research, Renton

Sponsors
All Listed Sponsors
lead

PhaseBio Pharmaceuticals Inc.

INDUSTRY